Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.34 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 4/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5084790 | 1.00 | FDPS (0.44) | FDPSDNM1LMNACA2OPRM1 | |
| Hydrochloric Acid SCHEMBL5092147 | 1.00 | FDPS (0.44) | FDPSDNM1LMNACA2OPRM1 | |
| Hydrochloric Acid SCHEMBL2886479 | 1.00 | FDPS (0.44) | FDPSDNM1LMNACA2OPRM1 | |
| Hydrochloric Acid SCHEMBL5085106 | 1.00 | FDPS (0.44) | FDPSDNM1LMNACA2OPRM1 | |
| Hydrochloric Acid SCHEMBL524626 | 1.00 | FDPS (0.44) | FDPSDNM1LMNACA2OPRM1 | |
| Hydrochloric Acid SCHEMBL5138884 | 1.00 | FDPS (0.44) | FDPSDNM1LMNACA2OPRM1 | |
| Hydrochloric Acid SCHEMBL5087140 | 1.00 | FDPS (0.44) | FDPSDNM1LMNACA2OPRM1 | |
| SCHEMBL1064108 | 0.98 | FDPS (0.46) | FDPSDNM1LMNACA2OPRM1 | |
| SCHEMBL1063958 | 0.98 | FDPS (0.46) | FDPSDNM1LMNACA2OPRM1 | |
| SCHEMBL1063393 | 0.98 | FDPS (0.46) | FDPSDNM1LMNACA2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381550-A1 | CARBON DISULFIDE TREATED MATERIALS AND METHODS OF PURIFYING FLUIDS USING THE SAME | ZENITH PURIFICATION LLC (US) | 2025-12-18 | — | — | US | claimed |
| US-20250313540-A1 | PROCESS FOR THE PREPARATION OF [1,4,5]-OXADIAZEPINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CN) | 2025-10-09 | — | — | US | claimed |
| CN-119156378-A | Process for the preparation of [1,4,5] -oxadiazepine derivatives | 先正达农作物保护股份公司 | 2024-12-17 | — | — | CN | claimed |
| US-20240010778-A1 | CHARGED SURFACTANT PARTICLES AND BRUSH POLYMERIC PARTICLES, METHODS OF MAKING SAME, AND USES THEREOF | CORNELL UNIVERSITY | 2024-01-11 | — | — | US | claimed |
| WO-2023208706-A1 | PROCESS FOR THE PREPARATION OF [1,4,5]-OXADIAZEPINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-11-02 | — | — | WO | claimed |
| CN-113274980-B | Vanadium oxide-organic molecular cage-based porous liquid and preparation method and application thereof | 南京工业大学 | 2022-12-06 | — | — | CN | claimed |
| CN-114206115-A | Compositions for treating and preventing bacterial growth on substrates | 马来西亚国家石油公司 | 2022-03-18 | — | — | CN | claimed |
| WO-2022056175-A1 | CHARGED SURFACTANT PARTICLES AND BRUSH POLYMERIC PARTICLES, METHODS OF MAKING SAME, AND USES THEREOF | CORNELL UNIVERSITY (US) | 2022-03-17 | — | — | WO | claimed |
| CN-114058020-A | Preparation method and application of quaternary phosphonium salt | 江苏康爱特环境工程集团有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-113274980-A | Vanadium oxide-organic molecular cage-based porous liquid and preparation method and application thereof | 南京工业大学 | 2021-08-20 | — | — | CN | claimed |
| US-7192776-B2 | Synthetic urine and method of manufacturing same | SPECTRUM LABORATORIES, LLC | 2007-03-20 | — | — | US | claimed |
| US-20040005286-A1 | Organic salt conditioner, organic salt-containing composition, and uses thereof | L'OREAL (FR) | 2004-01-08 | — | — | US | claimed |
| EP-0789595-A4 | SYNERGISTIC BIOCIDAL COMBINATIONS | BETZDEARBORN INC (US) | 2000-11-02 | — | — | EP | claimed |
| EP-0789595-A1 | SYNERGISTIC BIOCIDAL COMBINATIONS | BetzDearborn Inc (US) | 1997-08-20 | — | — | EP | claimed |
| WO-1996014092-A1 | SYNERGISTIC BIOCIDAL COMBINATIONS | BETZDEARBORN INC. (US) | 1996-05-17 | — | — | WO | claimed |
| US-5468739-A | Phosphonium | BETZ LABORATORIES, INC. (US) | 1995-11-21 | — | — | US | claimed |
| US-5372947-A | Determining amount of aldehyde released by conversion with respect to a sample from which existing aldehydes have been separated | CTS BIOCIDES LTD. (GB) | 1994-12-13 | — | — | US | claimed |
| EP-0610302-A1 | METHOD OF ANALYSIS | CTS BIOCIDES LTD. (GB) | 1994-08-17 | — | — | EP | claimed |
| WO-1993009430-A1 | METHOD OF ANALYSIS | CTS BIOCIDES LTD. (GB) | 1993-05-13 | — | — | WO | claimed |
| US-5102874-A | Synergistic | ECOLAB INC. (US) | 1992-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040005286-A1 | Organic salt conditioner, organic salt-containing composition, and uses thereof | KRT18, HCN4, PRKDC | CA2 290/4885OPRM1 2640/4885FDPS 4495/4885 |
| US-20250313540-A1 | PROCESS FOR THE PREPARATION OF [1,4,5]-OXADIAZEPINE DERIVATIVES | ADH1C, ADH1A, ADH5 | CA2 2478/4885OPRM1 67/4885FDPS 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.